Heron Therapeutics (HRTX) just unveiled an announcement.
Heron Therapeutics, Inc. recently announced that the FDA has received its application for the extended-release solution ZYNRELEF® and set a review completion goal date for September 23, 2024. This milestone could signify a significant development for the company and holds potential implications for investors tracking advances in pharmaceuticals and Heron’s market position.
Learn more about HRTX stock on TipRanks’ Stock Analysis page.
